Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

High soluble endoglin levels regulate cholesterol homeostasis and bile acids turnover in the liver of transgenic mice.

Dolezelova E, Sa ICI, Prasnicka A, Hroch M, Hyspler R, Ticha A, Lastuvkova H, Cermanova J, Pericacho M, Visek J, Lasticova M, Micuda S, Nachtigal P.

Life Sci. 2019 Sep 1;232:116643. doi: 10.1016/j.lfs.2019.116643. Epub 2019 Jul 9.

PMID:
31299237
2.

Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta.

Vitverova B, Blazickova K, Najmanova I, Vicen M, Hyšpler R, Dolezelova E, Nemeckova I, Tebbens JD, Bernabeu C, Pericacho M, Nachtigal P.

Atherosclerosis. 2018 Apr;271:15-25. doi: 10.1016/j.atherosclerosis.2018.02.008. Epub 2018 Feb 9.

PMID:
29459262
3.

Circulating soluble endoglin modifies the inflammatory response in mice.

Ruiz-Remolina L, Ollauri-Ibáñez C, Pérez-Roque L, Núñez-Gómez E, Pérez-Barriocanal F, López-Novoa JM, Pericacho M, Rodríguez-Barbero A.

PLoS One. 2017 Nov 16;12(11):e0188204. doi: 10.1371/journal.pone.0188204. eCollection 2017.

4.

Human endoglin as a potential new partner involved in platelet-endothelium interactions.

Rossi E, Pericacho M, Bachelot-Loza C, Pidard D, Gaussem P, Poirault-Chassac S, Blanco FJ, Langa C, González-Manchón C, Novoa JML, Smadja DM, Bernabeu C.

Cell Mol Life Sci. 2018 Apr;75(7):1269-1284. doi: 10.1007/s00018-017-2694-7. Epub 2017 Oct 28.

5.

Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies.

Ollauri-Ibáñez C, López-Novoa JM, Pericacho M.

Expert Opin Biol Ther. 2017 Sep;17(9):1053-1063. doi: 10.1080/14712598.2017.1346607. Epub 2017 Jul 10. Review.

PMID:
28656781
6.

High soluble endoglin levels do not induce changes in structural parameters of mouse heart.

Rathouska J, Fikrova P, Mrkvicova A, Blazickova K, Varejckova M, Dolezelova E, Nemeckova I, Vitverova B, Peslova L, Gallardo-Vara E, Pericacho M, Nachtigal P.

Heart Vessels. 2017 Aug;32(8):1013-1024. doi: 10.1007/s00380-017-0976-5. Epub 2017 Apr 5.

PMID:
28382387
7.

The role of endoglin in post-ischemic revascularization.

Núñez-Gómez E, Pericacho M, Ollauri-Ibáñez C, Bernabéu C, López-Novoa JM.

Angiogenesis. 2017 Feb;20(1):1-24. doi: 10.1007/s10456-016-9535-4. Epub 2016 Dec 9. Review.

PMID:
27943030
8.

Mechanisms of triple whammy acute kidney injury.

Prieto-García L, Pericacho M, Sancho-Martínez SM, Sánchez Á, Martínez-Salgado C, López-Novoa JM, López-Hernández FJ.

Pharmacol Ther. 2016 Nov;167:132-145. doi: 10.1016/j.pharmthera.2016.07.011. Epub 2016 Aug 1.

PMID:
27490717
9.

Endoglin regulates mural cell adhesion in the circulatory system.

Rossi E, Smadja DM, Boscolo E, Langa C, Arevalo MA, Pericacho M, Gamella-Pozuelo L, Kauskot A, Botella LM, Gaussem P, Bischoff J, Lopez-Novoa JM, Bernabeu C.

Cell Mol Life Sci. 2016 Apr;73(8):1715-39. doi: 10.1007/s00018-015-2099-4. Epub 2015 Dec 8.

10.

Heterozygous disruption of activin receptor-like kinase 1 is associated with increased arterial pressure in mice.

González-Núñez M, Riolobos AS, Castellano O, Fuentes-Calvo I, de los Ángeles Sevilla M, Oujo B, Pericacho M, Cruz-Gonzalez I, Pérez-Barriocanal F, ten Dijke P, López-Novoa JM.

Dis Model Mech. 2015 Nov;8(11):1427-39. doi: 10.1242/dmm.019695. Epub 2015 Sep 17.

11.

Immunosuppression-Independent Role of Regulatory T Cells against Hypertension-Driven Renal Dysfunctions.

Fabbiano S, Menacho-Márquez M, Robles-Valero J, Pericacho M, Matesanz-Marín A, García-Macías C, Sevilla MA, Montero MJ, Alarcón B, López-Novoa JM, Martín P, Bustelo XR.

Mol Cell Biol. 2015 Oct;35(20):3528-46. doi: 10.1128/MCB.00518-15. Epub 2015 Aug 3.

12.

L-Endoglin overexpression increases renal fibrosis after unilateral ureteral obstruction.

Oujo B, Muñoz-Félix JM, Arévalo M, Núñez-Gómez E, Pérez-Roque L, Pericacho M, González-Núñez M, Langa C, Martínez-Salgado C, Perez-Barriocanal F, Bernabeu C, Lopez-Novoa JM.

PLoS One. 2014 Oct 14;9(10):e110365. doi: 10.1371/journal.pone.0110365. eCollection 2014.

13.

Endoglin haploinsufficiency promotes fibroblast accumulation during wound healing through Akt activation.

Pericacho M, Velasco S, Prieto M, Llano E, López-Novoa JM, Rodríguez-Barbero A.

PLoS One. 2013;8(1):e54687. doi: 10.1371/journal.pone.0054687. Epub 2013 Jan 17.

14.

Alteration in endoglin-related angiogenesis in refractory cytopenia with multilineage dysplasia.

del Rey M, Pericacho M, Velasco S, Lumbreras E, López-Novoa JM, Hernández-Rivas JM, Rodríguez-Barbero A.

PLoS One. 2013;8(1):e53624. doi: 10.1371/journal.pone.0053624. Epub 2013 Jan 16.

15.

C3G transgenic mouse models with specific expression in platelets reveal a new role for C3G in platelet clotting through its GEF activity.

Gutiérrez-Herrero S, Maia V, Gutiérrez-Berzal J, Calzada N, Sanz M, González-Manchón C, Pericacho M, Ortiz-Rivero S, González-Porras JR, Arechederra M, Porras A, Guerrero C.

Biochim Biophys Acta. 2012 Aug;1823(8):1366-77. doi: 10.1016/j.bbamcr.2012.05.021. Epub 2012 May 29.

16.

Diminished thrombogenic responses by deletion of the Podocalyxin Gene in mouse megakaryocytes.

Pericacho M, Alonso-Martín S, Larrucea S, González-Manchón C, Fernández D, Sánchez I, Ayuso MS, Parrilla R.

PLoS One. 2011;6(10):e26025. doi: 10.1371/journal.pone.0026025. Epub 2011 Oct 7.

17.

Release of podocalyxin into the extracellular space. Role of metalloproteinases.

Fernández D, Larrucea S, Nowakowski A, Pericacho M, Parrilla R, Ayuso MS.

Biochim Biophys Acta. 2011 Aug;1813(8):1504-10. doi: 10.1016/j.bbamcr.2011.05.009. Epub 2011 May 15.

18.

The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation.

Dorado F, Velasco S, Esparís-Ogando A, Pericacho M, Pandiella A, Silva J, López-Novoa JM, Rodríguez-Barbero A.

Nephrol Dial Transplant. 2008 Nov;23(11):3403-11. doi: 10.1093/ndt/gfn333. Epub 2008 Jun 21.

PMID:
18567890
19.

Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction.

Cruz-Gonzalez I, Pabón P, Rodríguez-Barbero A, Martín-Moreiras J, Pericacho M, Sánchez PL, Ramirez V, Sánchez-Ledesma M, Martín-Herrero F, Jiménez-Candil J, Maree AO, Sánchez-Rodríguez A, Martín-Luengo C, López-Novoa JM.

J Cell Mol Med. 2008 Jun;12(3):955-61. doi: 10.1111/j.1582-4934.2008.00156.x.

20.

L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts.

Velasco S, Alvarez-Muñoz P, Pericacho M, Dijke PT, Bernabéu C, López-Novoa JM, Rodríguez-Barbero A.

J Cell Sci. 2008 Mar 15;121(Pt 6):913-9. doi: 10.1242/jcs.023283. Epub 2008 Feb 26.

21.

Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients.

Ocaña A, Rodríguez-Barbero A, Pericacho M, Bellido L, Seijas R, López R, Delgado C, de Prado DS, Cruz-Hernández JJ, López-Novoa JM.

Cancer Lett. 2007 Sep 18;255(1):71-6. Epub 2007 May 4.

PMID:
17482348
22.

Gene expression fingerprinting for human hereditary hemorrhagic telangiectasia.

Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F, Pericacho M, Rodriguez-Barbero A, Eleno N, Lopez-Novoa JM, Düwell A, Vega MA, Bernabeu C, Botella LM.

Hum Mol Genet. 2007 Jul 1;16(13):1515-33. Epub 2007 Apr 9. Erratum in: Hum Mol Genet. 2007 Nov 1;16(21):2649. Fernandez-Lopez, Africa [corrected to Fernandez-L, Africa].

PMID:
17420163
23.

Endoglin regulates cyclooxygenase-2 expression and activity.

Jerkic M, Rivas-Elena JV, Santibanez JF, Prieto M, Rodríguez-Barbero A, Perez-Barriocanal F, Pericacho M, Arévalo M, Vary CP, Letarte M, Bernabeu C, López-Novoa JM.

Circ Res. 2006 Aug 4;99(3):248-56. Epub 2006 Jul 13.

24.

Reduced angiogenic responses in adult Endoglin heterozygous mice.

Jerkic M, Rodríguez-Barbero A, Prieto M, Toporsian M, Pericacho M, Rivas-Elena JV, Obreo J, Wang A, Pérez-Barriocanal F, Arévalo M, Bernabéu C, Letarte M, López-Novoa JM.

Cardiovasc Res. 2006 Mar 1;69(4):845-54. Epub 2006 Jan 10.

Supplemental Content

Loading ...
Support Center